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Protein homeostasis (proteosta-
sis) is at the core of cellular func-
tions. The European network
PROTEOSTASIS was created to
steer research and foster collabo-
rations in the interconnected ﬁelds
of posttranslational modiﬁcations
by ubiquitin family members and
protein turnover by proteasome,
autophagy, and lysosomal sys-
tems in health and diseases,
across the kingdoms of life.
Proteostasis: The Topic
Proteostasis, the portmanteau of protein
andhomeostasis, is the term for theunder-
lying molecular network balancing the
entire proteome of a living organism. PRO-
TEOSTASIS isalso the runningnameofour
recently terminated COST Action
BM1307i,ii[112_TD$DIFF] ‘European network to integrate
research on intracellular proteolysis path-
ways in health and disease’ from the Bio-
medicine and Molecular Biosciences area
of COST [113_TD$DIFF](European Cooperation in Sci-
ence and Technology, funding period April
2014–April 2018; cost-proteostasis.eu).
The average number of proteins per indi-
vidual cell is substantial and differs among
species. In the single yeast cell, there are
roughly 6000 different proteins [1] sum-
ming up to 42–50 million protein mole-
cules [1–3], while in human cells there are
more than 10 000 different proteins per
cell for a total of 2–3 billion protein mol-
ecules at any given time [4,5]. Possible
proteoforms occur on top of those num-
bers with variable concentrations and
diverse distributions throughout the cell
types of multicellular organisms. This
striking complexity requires tight regula-
tion on multiple levels that is achieved
[114_TD$DIFF]through robust and highly sophisticated
mechanisms. Indeed, broadly more than
5% of all proteins throughout the king-
doms are involved in protein synthesis
and turnover, highlighting the global
importance of these processes [6–8].
Despite much progress over the past
decades, understanding how these com-
plex proteomes are constantly and
dynamically monitored and remodeled
remains an enormous challenge.
Proteostasis refers to the biological
mechanisms controlling the biosynthesis,
co- and posttranslational processing,
folding, trafﬁcking, neofunctionalization
(i.e., changes in protein function), and
degradation of proteins in vivo. Among
these processes, intracellular proteolysis
is critical not only for survival and cellular
homeostasis of all living cells under
unchallenged conditions but also for rapid
proteome remodeling in response to
many environmental stresses. Further-
more, disturbed proteostasis may lead
either to the accumulation of normally
degraded proteins or to excessive protein
degradation. Those processes can be
associated with aging and many patholo-
gies, such as cancer and immune and
neurological disorders in humans as well
as other diseases and responses to envi-
ronmental stresses in plants and other
organisms across the kingdoms of life.
Overall, since proteostasis plays pivotal
roles in almost every biological process,
including general growth and develop-
ment in all organisms and mechanisms
as diverse as heart development and
plant tolerance to ﬂooding, for example,
its analysis has elevated the interest of
scientists from diverse backgrounds
and with different research foci. A wide
variety of research approaches is used to
identify the mechanisms that regulate
proteostasis, typically involving a breadth
of model organisms (fungi, invertebrates,
vertebrates, or plants) and different meth-
odologies. This heterogeneity might
restrain researchers into their own scien-
tiﬁc niche, impairing knowledge exchange
between ﬁelds that are in fact linked in real
life. The PROTEOSTASIS network was
built upon the conviction that connecting
the different areas of research in this ﬁeld
would result in a boost of scientiﬁc
exchange and sharing and set the stage
for an advance of our community knowl-
edge through new possibilities of
exchange and collaboration.
One central aspect of proteostasis is
protein degradation. Often referred to
as proteolysis, it has been studied for
decades, with publications on this topic
constantly increasing since the 1970s.
Two major intracellular proteolysis path-
ways, namely, the autophagy-lysosomal
pathway (ALP) and the ubiquitin-protea-
some system (UPS), synergistically play
critical roles inside cells for the mainte-
nance of cellular homeostasis and organ-
ism (patho)physiology. Thanks to the
ever-increasing understanding of these
pathways, and also to recent technical
developments in cell imaging, proteo-
mics, and more generally ‘-omics’ stud-
ies, we now realize that these research
ﬁelds are strongly entwined and
coordinated.
The small 8-kDa ‘ubiquitous’ protein
ubiquitin (Ub) is a common endogenous
molecular tag working as posttransla-
tional protein modiﬁcation used by both
UPS and ALP to control the stability of
most, if not all, proteins in a highly speciﬁc
and regulated manner. Because of its
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central role in cell metabolism, Ub is
thus commonly accepted as a critical sig-
nature for the engagement of these
sophisticated intracellular machineries.
However, Ub also exerts proteolysis-
independent functions, such as regulation
of signaling pathways, transcription, or
protein trafﬁcking. Also in the ERAD
(endoplasmic reticulum-associated pro-
tein degradation) system, Ub plays an
important role in cargo retrotranslocation
that ﬁnally also concludes in proteolysis
via the proteasome. The ﬁeld expanded
by understanding that Ub is just a mem-
ber of a family of Ub-like proteins (UbLs)
that cooperate together to ﬁne-tune the
intracellular proteome. The most studied
UbLs, such as SUMO (small Ub-like mod-
iﬁer) or NEDD8 (neural precursor cell
expressed, developmentally down-regu-
lated 8), are extremely versatile and
crosstalk, that is, functionally interact in
a dynamic manner with various modes of
posttranslational modiﬁcations of target
proteins by Ub, modulating the fate of
cellular proteins in response to external
and intracellular stimuli.
PROTEOSTASIS: The Network
Even if we still do not clearly understand
when, how, and why many proteostatic
systems function and collaborate within
the cell, they enable alternative solutions
to complicated problems, ranging from
protein degradation to relocalization and
neofunctionalization, and increase cellular
plasticity for adaptation and survival in a
continuously changing environment.
Addressing all of these aspects of proteo-
stasis was the ambition of the PROTEO-
STASIS network (Figure 1).
To be able to dissect the molecular bases
of complex proteostatic systems, in the
health and disease of multiple species
and with numerous approaches, we
nurtured synergies between research
groups to bridge the gap between parallel
but closely related ﬁelds, bringing
together researchers working on various
processes in different organisms, using
diverse but complementary approaches.
By reaching hundreds of European scien-
tists working on protein homeostasis,
PROTEOSTASIS offered the possibility
to develop a large exchange space that
broke artiﬁcial but real barriers, thus
unleashing connectivity and creativity in
our ﬁeld.
The COST Action PROTEOSTASIS coor-
dinated and integrated efforts made by
research teams in different areas to trans-
late novel discoveries into products of
clinical and/or economical value. In other
words, PROTEOSTASIS grew a fertile
ground to impulse a comprehensive
and holistic approach to tackle scientiﬁc
challenges, by capitalizing on our diversity
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Figure 1. A Scientiﬁc Field in Constant Development: PROTEOSTASIS Areas of Study.
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and complementary expertise, potentiat-
ing the resources and competencies
available in each group.
As a networking tool, PROTEOSTASIS
was successful in engaging more
than 270 research groups, including
researchers from 30 countries who cov-
ered all scientiﬁc areas of proteostasis.
The main goal of PROTEOSTASIS was
to foster exchanges between ﬁelds that
tended to ignore each other for years by
facilitating collaborative research and
broad scientiﬁc exchange. To bring
together expertise from different disci-
plines and to openly discuss recent
scientiﬁc developments, researchers
from diverse backgrounds were invited
to actively participate and join the com-
munity. Special emphasis was placed
on the transfer from basic to transla-
tional science, novel technologies,
and training next-generation scientists.
Sharing unpublished data was the
rule during the meetings organized by
PROTEOSTASIS in the past 4 years.
This strongly promoted collaboration
among experienced and early-stage
academic-, clinical-, and industry-
based researchers.
PROTEOSTASIS was structured around
six wide thematic blocks, covering a
broad and complementary scientiﬁc
spectrum within protein homeostasis.
Protein Modiﬁcation dealt with molecu-
lar and structural properties of proteo-
static components; Proteolytic Systems
gathered scientists around mechanisms
and structures of intracellular proteolytic
systems such as proteasomes, autoph-
agy, lysosomes, and apoptosis; Cell
MeeƟngs and conferences (M and C)
Training schools (TS)
Short-Term ScienƟfic Missions (STSMs)
2014 2015 2016 2017 2018
18 
STSMs
13 
STSMs
8 
STSMs
8 
STSMs
Kickoﬀ
M and C
• 1st acƟon meeƟng Spain 
• Neuroacanthocytosis Italy
M and C
• 2nd acƟon meeƟng CroaƟa 
• Yeast apoptosis Portugal 
• Proteasome France
M and C
• 3rd acƟon MeeƟng Portugal
• Plant proteostasis Spain
• Apoptosis Spain 
•Zomes IX Italy
M and C
• N-Term Germany
• Ub & SUMO CroaƟa
• Proteasome Germany
• Vesicles Portugal
Final meeƟng
TS
• Aging Greece
• Ub and UbLs Italy
TS
• Ub and SUMO France
• Ub and UbLs Italy
TS
• Ub and UbL Italy
• Redox Greece
TS
• Ub and SUMO France
• Ub and autophagy Italy
• 4th acƟon meeƟng Greece 
Proteostasis ?meline of ac?vi?es
Figure 2. Achievements and Milestones of the PROTEOSTASIS Network: An Overview of Activities and New Funded Networks. Abbreviations:
SUMO, small Ub-like modiﬁer; Ub, ubiquitin; UbLs, Ub-like proteins.
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Signaling focused on signaling cas-
cades, protein trafﬁcking, and transcrip-
tional regulation; Quality Control
covered folding and misfolding, chaper-
ones, aggregation, and ERAD; Cell Pro-
liferation and Differentiation touched
many aspects of cell cycle, cell growth,
and development; and Diseases and
Biotechnology explored the molecular
basis of diseases and biomarkers in
cancer, inﬂammation, and neurodegen-
eration, addressing drug targets and
biotechnology.
Activities, Outcomes, and
Highlights
Whether from the academic or the pri-
vate sector, the PROTEOSTASIS net-
work helped scientists to develop
fundamental or translational research
thanks to the multiple instruments that
it offered to the community, namely, the
organization or co-organization of 14
scientiﬁc meetings and workshops,
eight training schools, and 47 scientiﬁc
staff exchanges. Additional dissemina-
tion instruments included the website
(cost-proteostasis.eu), webinars, news-
letters, and social mediai–v [115_TD$DIFF] (Figure 2).
The co-organization of workshops
and other activities together with rele-
vant European or national bodies in
the life sciences such as EMBO, FEBS,
and other scientiﬁc societies was instru-
mental. The meetings, workshops, and
conferences covered broadly the
topics of theproteasomeand signalosome
complexes; autophagy; aging and neuro-
degeneration; apoptosis and cell death;
cell polarity and movement; vesicular biol-
ogy; system biology; Ub, SUMO, and
other UbLs; N-end rule pathway; protein
degradation in plants; agronomy[116_TD$DIFF], biotech-
nology and bioeconomy. Two examples
of these meetings, ZOMES IX – ‘PCI com-
plexes and ubiquitin deﬁning a hub for
protein homeostasis’ and ‘N-term 2017–
Proteostasis via the N-terminus’,
were described in meeting reports else-
where [9,10]. As a result of the N-term
2017 meeting, the International
Society of Protein Termini (http://ispt.
world/) was established for scientists
with a shared interest in protein N- and
C-terminal modiﬁcations and their
effectsonprotein functions.Theeight train-
ingschoolsaimedto teachtheanalysisof in
vitro and in vivo processes of ubiquitylation
andSUMOylation, theproteostaticbasisof
aging and redox regulation of metabolic
processes, and Ub-assisted autophagy.
Regarding networking, PROTEOSTASIS
facilitated the consolidation or the initia-
tion of collaborations and the generation
of novel international consortia dedicated
to speciﬁc issues. Those resulted in more
than 50 joint publications in peer-
reviewed scientiﬁc journals plus the three
thematic books Proteostasis, SUMO, and
Plant Proteostasis, with additional 74
contributions of network members [11–
13]. Importantly, the international scien-
tiﬁc exchanges enabled the mobility of
researchers between laboratories and
the development of joint research proj-
ects that were successfully funded.
Examples of those are TrainERS (train-
ers.eu) on endoplasmic reticulum stress;
META-CAN (metacan.eu), combining
cancer metabolism, cell death, cancer
immunity, data analysis, and immunome-
tabolism; UbiCODE (ubicode.eu), deci-
phering the mechanistics of the Ub
code; and TRIM-NET, exploring the func-
tions of TRIM E3 ligases (Figure 2). Future
joint applications are in the planning
stages among members of the network.
Conclusions
The goal of PROTEOSTASIS was to fos-
ter and concentrate interdisciplinary sci-
entiﬁc exchange and development of
novel research ideas. The network coor-
dinated and integrated the efforts made
by research teams to better understand
protein homeostasis and facilitated the
interchange with the private sector. The
network has contributed signiﬁcantly
towards reversing the national and
scientiﬁc fragmentation of research efforts
within the European research area and
beyond. After four exciting years of activi-
ties, we look back at a wonderful time of
multifaceted exciting research, exchange
of data and ideas, networking, training,
and numerous newly built interactions
and joint collaborations. PROTEOSTASIS
as a network, including its social media
and website activitiesii–v [117_TD$DIFF], is continued
after the ending of the funding period. It
will serve as a platform to communicate
science, assist to organize meetings and
conferences, and launch proposals in rel-
evant funding calls. We aim to preserve
those in the long term to facilitate and
foster future interactions. We believe this
type of network will be useful to other
areas of research that might experience
ﬁeld fragmentation.
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Trefoil Factor Family:
Unresolved Questions
and Clinical
Perspectives
Nayara Braga Emidio,1,6
Werner Hoffmann,2,6
Stuart M. Brierley,3,4 and
Markus Muttenthaler1,5,*
The trefoil factor family of peptides
(TFF1, TFF2, TFF3) with their lectin
activities play important roles in
mucosal protection and repair.
However, major gaps in under-
standing their molecular function
have hampered therapeutic devel-
opment for gastrointestinal disor-
ders. We provide here a critical
overview of the status quo.
The Trefoil Factor [122_TD$DIFF] amily (TFF):
Key Players in Mucosal
Protection and Repair
The three TFF peptides (TFF1, TFF2,
TFF3) are typical constituents of
mucous epithelia such as the alimen-
tary, respiratory, and urogenitary tracts,
the conjunctiva, and the inner ear,
where they are typically cosecreted with
mucins [1,2]. The major expression site
for TFF1 and TFF2 is the stomach, and
for TFF3 it is the intestine [1]. TFF pep-
tides appear also in the saliva, gastric
juice, urine, blood, and breast milk [1,3].
Pathologically, TFF peptides are ectopi-
cally expressed after wounding, in
inﬂammatory diseases, and in various
tumors [1]. They are also secreted in
an endocrine manner, for example, in
the immune and central nervous sys-
tems [1,4]. Numerous in vivo and in vitro
studies point to TFF peptides as key
players in mucosal protection and repair
processes. Accordingly, TFF peptides
are constituents of the mucus barrier,
where they display lectin-like behavior,
[123_TD$DIFF]and enhance mucosal restitution (cell
migration), while modulating cell junc-
tions, apoptosis, angiogenesis, and
mucosal differentiation processes [1].
Furthermore, transgenic TFF-deﬁcient
mice display abnormalities in the gas-
trointestinal (GI) tract and the immune
system [1].
Therapeutic Potential
Based on a diverse range of GI injury
models [1], TFFs hold particular therapeu-
tic promise not only for GI inﬂammatory
disorders but also for oral mucositis [5,6].
However, translation of this GI therapeutic
potential has been limited to a single
Phase I/II trial (16 patients) where recom-
binant TFF3 in enemas was given in com-
bination with orally delivered mesalazine
for the treatment of ulcerative colitis [1]. In
this study, no additional improvement
was observed compared to mesalazine
treatment alone; however, the small trial
size combined with limited understanding
of the mode of action of [124_TD$DIFF]the TFFs limits the
interpretation of these outcomes. More
successful was the therapeutic
[125_TD$DIFF]application of the TFF peptides in oral
mucositis, a side effect of radio- and che-
motherapy. In a Phase I trial, AG013, a
mouth-rinse formulation of Lactococcus
lactis secreting TFF1, reduced oral muco-
sitis in cancer patients receiving chemo-
therapy [6]. AG013 has been granted
Orphan Drug status in the EU and Fast
Track designation by the US Food and
Drug Administration, and is currently in
Phase II trials. In addition, homodimeric
TFF3 was also well tolerated in a Phase II
study and reduced the incidence and
severity of chemotherapy-induced oral
mucositis in cancer patients [5]. Both trials
support the therapeuticpotential of [126_TD$DIFF]theTFF
and highlight different delivery strategies.
Mechanisms of Action: Potential
Interaction Partners
We still know very little about the
molecular mechanisms of [116_TD$DIFF]the TFF
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